TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9928578

Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Castration
Number of subjects: 0

Group type: COMPARATOR
Intervention: CEF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose-escalating CEF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three cycles of CEF followed by high-dose chemotherapy and autologous stem cell support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy for 2 years
Number of subjects: 0
Study: 7920018

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3241121

Group type: EXPERIMENTAL
Intervention: Fish oil test meal after a fish oil-based diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saturated fat test meal after a saturated fat diet
Number of subjects: 21
Study: 29159589

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 49
Study: 28077338

Group type: EXPERIMENTAL
Intervention: 10-day B-quadruple therapy (OM-triple + bismuth subcitrate 120 mg four times daily)
Number of subjects: 351

Group type: COMPARATOR
Intervention: 10-day omeprazole-based triple therapy (OM-triple; omeprazole 20 mg twice daily, clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: B-quadruple therapy
Number of subjects: 351
Study: 25640470

Group type: EXPERIMENTAL
Intervention: Omalizumab (750 mg monthly)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 23661521

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5‐15 mg)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Sodium Valproate (600‐1000 mg)
Number of subjects: 201
Study: 22029858

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 165
Study: 18285565

Group type: EXPERIMENTAL
Intervention: Myoblasts (400 million; n=33)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Myoblasts (800 million; n=34)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo (n=30)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: High-dose myoblasts
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Myoblasts (combined treatment)
Number of subjects: 97
Study: 17159171

Group type: EXPERIMENTAL
Intervention: Intra-articular bupivacaine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intra-articular saline
Number of subjects: 35
Study: 12661679

Group type: EXPERIMENTAL
Intervention: Explanation for why the objects were the same shape (Study 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information about the function of a named target object (Study 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No information about the function of a named target object (Study 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Told the function that object could fulfill (Study 2)
Number of subjects: 0
Study: 15692117

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tadalafil
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 10901601

Group type: EXPERIMENTAL
Intervention: Resorbable matrix barrier (test)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Non-resorbable barrier (control)
Number of subjects: 11
Study: 8559495

Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs (ditazole, ticlopidine, aspirin plus dipyridamole)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: No antiplatelet drugs
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (uraemic patients not on rHuEpo therapy)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs
Number of subjects: 18
Study: 2076621

Group type: EXPERIMENTAL
Intervention: Epitrain
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (Tubigrip)
Number of subjects: 35
Study: 7419011

Group type: EXPERIMENTAL
Intervention: Intravenous fat (20 g of Intralipid)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intraduodenal fat (20 g of Intralipid)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intravenous amino acids (21 g L‐amino acids; Freamine II) plus glucose (50 g)
Number of subjects: 5
Study: 30776476

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1800 mg containing 1206 mg EPA) for 12 weeks
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 108
Study: 30640652

Group type: EXPERIMENTAL
Intervention: 2 mg of perineural dexamethasone
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 5 mg of perineural dexamethasone
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 8 mg of perineural dexamethasone
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 360
Study: 28673322

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with donepezil
Number of subjects: 334

Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 334
Study: 26419363

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IE/day for 1 year)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 23524017

Group type: EXPERIMENTAL
Intervention: Supratherapeutic doses of salbutamol (SALB) 200 μg (3 doses at 20 min intervals)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Supratherapeutic doses of ipratropium bromide (IPR) 20 μg, 20 μg, and 40 μg (at 20 min intervals)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Supratherapeutic doses of salbutamol (SALB) 200 μg (3 doses at 20 min intervals) after MABA 1200
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Supratherapeutic doses of ipratropium bromide (IPR) after MABA 1200
Number of subjects: 44
Study: 22002970

Group type: EXPERIMENTAL
Intervention: ¡Si, Yo Puedo Controlar Mi Diabetes! diabetes self-management education program
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (wait list)
Number of subjects: 144
Study: 19515536

Group type: EXPERIMENTAL
Intervention: Extended release MET (500 to 1000 mg daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Extended release MET
Number of subjects: 61
Study: 17597827

Group type: EXPERIMENTAL
Intervention: LED phototherapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: BB phototherapy
Number of subjects: 66
Study: 15524061

Group type: EXPERIMENTAL
Intervention: Immediate hemodialysis after PTA
Number of subjects: 66

Group type: COMPARATOR
Intervention: Next day hemodialysis after PTA
Number of subjects: 66
Study: 11499332

Group type: EXPERIMENTAL
Intervention: Oral terbinafine 250 mg once daily for 2 or 4 weeks
Number of subjects: 27
Study: 9643531

Group type: EXPERIMENTAL
Intervention: CDE plus saquinavir (600mg PO TID)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CDE without saquinavir (from prior study)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CDE plus saquinavir
Number of subjects: 12
Study: 8159103

Group type: EXPERIMENTAL
Intervention: Dilevalol 400 mg x 1
Number of subjects: 42

Group type: COMPARATOR
Intervention: Metoprolol succinate 200 mg x 1
Number of subjects: 42
Study: 29689045

Group type: EXPERIMENTAL
Intervention: Parenting group intervention (visits by child development agents and fortnightly meetings)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Parenting group intervention
Number of subjects: 526
Study: 28416195

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 252

Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 252
Study: 26755466

Group type: EXPERIMENTAL
Intervention: Cognitive-existential group therapy (12 sessions of 90 minutes twice per week)
Number of subjects: 22
Study: 22584916

Group type: EXPERIMENTAL
Intervention: CD4-guided planned treatment interruptions (PTIs)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Continuous therapy (CT)
Number of subjects: 109
Study: 21358200

Group type: EXPERIMENTAL
Intervention: Finafloxacin 200 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Finafloxacin 800 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Finafloxacin in acidic urine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Finafloxacin in alkaline urine
Number of subjects: 6
Study: 17574675

Group type: EXPERIMENTAL
Intervention: Submacular surgery
Number of subjects: 690

Group type: COMPARATOR
Intervention: Ophthalmologist's assessment of lens opacity
Number of subjects: 690

Group type: COMPARATOR
Intervention: Fundus photograph quality
Number of subjects: 690
Study: 17182987

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage with quantitative culture
Number of subjects: 740

Group type: COMPARATOR
Intervention: Endotracheal aspiration with nonquantitative culture
Number of subjects: 740
Study: 14578411

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10744200

Group type: EXPERIMENTAL
Intervention: 0.05% mequitazine eyedrops
Number of subjects: 22

Group type: COMPARATOR
Intervention: 2% disodium cromoglycate eyedrops
Number of subjects: 22
Study: 8833554

Group type: EXPERIMENTAL
Intervention: PCA morphine: 1 mg with 6-minute lockout
Number of subjects: 34

Group type: COMPARATOR
Intervention: PCACI: PCA morphine 1 mg with 6-minute lockout plus 0.5-1 mg/h continuous infusion
Number of subjects: 34
Study: 1558438

Group type: EXPERIMENTAL
Intervention: Theophylline treatment (oral, 7 days, plasma level 87.7 +/‐ 7.8 mumol/L)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2859183

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 29511170

Group type: EXPERIMENTAL
Intervention: Aerosolized LASAG
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 26846859

Group type: EXPERIMENTAL
Intervention: Thrombus with Δ≥10.9 HU (n=81, 44%)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Thrombus with ε≥6.5% (n=77, 42%)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Thrombus perviousness (Δ and ε)
Number of subjects: 184
Study: 25141137

Group type: EXPERIMENTAL
Intervention: 10-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily, amoxicillin 1 g twice daily, esomeprazole 40 mg twice daily)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 14-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily, amoxicillin 1 g twice daily, esomeprazole 40 mg twice daily)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 10-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily) with levofloxacin-susceptible strains
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 10-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily) with levofloxacin-resistant strains
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 14-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily) with levofloxacin-susceptible strains
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 14-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily) with levofloxacin-resistant strains
Number of subjects: 158
Study: 22738608

Group type: EXPERIMENTAL
Intervention: Cirrus HD spectral‐domain optical coherence tomography (OCT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (70 healthy young subjects, mean age 22.66 years)
Number of subjects: 36
Study: 20375351

Group type: EXPERIMENTAL
Intervention: Web-based intervention plus usual care
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 62
Study: 18719005

Group type: EXPERIMENTAL
Intervention: Observational rating of gait variability
Number of subjects: 46

Group type: COMPARATOR
Intervention: Stance time variability derived from computerized walkway
Number of subjects: 46
Study: 16042022

Group type: EXPERIMENTAL
Intervention: Picture naming in Alzheimer's patients using commonly used analyses for single cases (chi2 and z-scores)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Picture naming in a different group of Alzheimer's patients using the same techniques (chi2 and z-scores)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Picture naming in the same Alzheimer's patients using stimuli that did not produce ceiling effects/skewed distributions and statistical methods that did not treat the control sample as a population
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 11788212

Group type: EXPERIMENTAL
Intervention: Intravenous followed by oral conjugated estrogen for 21 days
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Intravenous estrogen followed by oral conjugated estrogen plus medroxyprogesterone for 21 days
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study: 10811511

Group type: EXPERIMENTAL
Intervention: PTA and Strecker-stent (n=15)
Number of subjects: 32

Group type: COMPARATOR
Intervention: PTA alone (n=17)
Number of subjects: 32
Study: 7807041

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 2111627

Group type: EXPERIMENTAL
Intervention: Nalbuphine (10 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl (100 micrograms)
Number of subjects: 60
Study: 6992914

Group type: EXPERIMENTAL
Intervention: Lateral paramedian incision
Number of subjects: 207

Group type: COMPARATOR
Intervention: Midline incision
Number of subjects: 207

Group type: COMPARATOR
Intervention: Medial paramedian incision
Number of subjects: 207
Study: 31416459

Group type: EXPERIMENTAL
Intervention: Umoyo clinics
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control facilities
Number of subjects: 28
Study: 28522452

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo surgery
Number of subjects: 146
Study: 27466224

Group type: EXPERIMENTAL
Intervention: 3 mL Hyaluronic Acid (HA) injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3 mL saline solution (placebo)
Number of subjects: 60
Study: 24401765

Group type: EXPERIMENTAL
Intervention: Prochlorperazine 5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23138710

Group type: EXPERIMENTAL
Intervention: 0.12% CHX-based mouthrinse
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 16
Study: 20056649

Group type: EXPERIMENTAL
Intervention: Calcium (2 g/d)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) (800 IU/d)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Calcium plus Vitamin D(3)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 18844764

Group type: EXPERIMENTAL
Intervention: Self blood pressure monitoring (SBPM)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Monitor possession
Number of subjects: 578
Study: 16034227

Group type: EXPERIMENTAL
Intervention: Oral baclofen
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 21
Study: 14551096

Group type: EXPERIMENTAL
Intervention: Compliance therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-specific counselling
Number of subjects: 56
Study: 10545429

Group type: EXPERIMENTAL
Intervention: Reteplase 10+10-U double bolus (n=50)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 MU/60 min; n=10)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Accelerated alteplase (100 mg/90 min; n=21)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional alteplase (100 mg/180 min; n=15)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Reteplase 10+5-U double bolus (n=15)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Reteplase 15-U single bolus (n=15)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Reteplase (10+10 U) and streptokinase
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 126
Study: 9091371

Group type: EXPERIMENTAL
Intervention: Lacrimal plug insertion in the inferior canaliculus
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (contralateral eye without plug)
Number of subjects: 9
Study: 1807971

Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 108
Study: 6318350

Group type: EXPERIMENTAL
Intervention: Bi‐Profenid 150 mg (one 150 mg tablet twice daily for 2 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional forms (two 50 mg Profenid capsules each morning and noon with one 100 mg suppository each evening for 2 days)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bi‐Profenid 150 mg
Number of subjects: 32
Study: 31835978

Group type: EXPERIMENTAL
Intervention: Platelet transfusion during rewarming phase (10 mL/kg)
Number of subjects: 46
Study: 29731182

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus helveticus and Bifidobacterium longum)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Prebiotic (galactooligosaccharide)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Probiotic
Number of subjects: 110
Study: 27731924

Group type: EXPERIMENTAL
Intervention: Coaxial mini-incision (2.4 mm) phacoemulsification
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sleeveless microincision (1.1 mm) phacoemulsification
Number of subjects: 20
Study: 25458091

Group type: EXPERIMENTAL
Intervention: Medullary canal saline irrigation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional TKA without irrigation
Number of subjects: 30
Study: 24443618

Group type: EXPERIMENTAL
Intervention: trastuzumab-based chemotherapy
Number of subjects: 114
Study: 22527062

Group type: EXPERIMENTAL
Intervention: In-line filtration
Number of subjects: 807
Study: 19686587

Group type: EXPERIMENTAL
Intervention: Multidimensional home-based exercise programme consisting of physical activity counselling, home-exercise programme, and exercise consultations.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Multidimensional home-based exercise programme.
Number of subjects: 90
Study: 17412737

Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg at weeks 0, 2, 6, 14 and 22
Number of subjects: 28

Group type: COMPARATOR
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 28

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Infliximab and Etanercept
Number of subjects: 28
Study: 15223109

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 10963245

Group type: EXPERIMENTAL
Intervention: Self-management of oral anticoagulant therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Management by the anticoagulation clinic
Number of subjects: 50
Study: 8640434

Group type: EXPERIMENTAL
Intervention: Intracameral gentamicin
Number of subjects: 97

Group type: COMPARATOR
Intervention: No intracameral antibiotics (control group)
Number of subjects: 97
Study: 1531090

Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg per day for 28 days)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 6323525

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Systemic acyclovir
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Antibody to gD and vp66
Number of subjects: 63
Study: 31628930

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU intranasally)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 29239664

Group type: EXPERIMENTAL
Intervention: SR paracetamol 2×1000 mg BID
Number of subjects: 676

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 676
Study: 26980471

Group type: EXPERIMENTAL
Intervention: Necitumumab plus gemcitabine-cisplatin
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin
Number of subjects: 1093
Study: 22512511

Group type: EXPERIMENTAL
Intervention: SCIP intervention
Number of subjects: 57
Study: 20116153

Group type: EXPERIMENTAL
Intervention: Dialysis dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urea kinetic modeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different modalities of dialysis
Number of subjects: 0
Study: 18991814

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 64
Study: 15520832

Group type: EXPERIMENTAL
Intervention: DraI polymorphism of the ADRA2A gene
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Haplotype containing the less common allele of the DraI polymorphism
Number of subjects: 177
Study: 12579017

Group type: EXPERIMENTAL
Intervention: Dynamically locked intramedullary hip screw (Group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Classically locked intramedullary hip screw (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (Group A and Group B)
Number of subjects: 80
Study: 11109233

Group type: EXPERIMENTAL
Intervention: Imagery-rehearsal therapy (treatment group)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Wait-list control (control group)
Number of subjects: 169
Study: 8845036

Group type: COMPARATOR
Intervention: Oral vaccination with whole cell/B subunit (CTB) cholera vaccine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Local intravaginal vaccination with whole cell/B subunit (CTB) cholera vaccine mixed with eldexomer gel
Number of subjects: 14
Study: 1341234

Group type: EXPERIMENTAL
Intervention: Group B: approximately 3.0 g d‐1 sodium sulphate in juice
Number of subjects: 69

Group type: COMPARATOR
Intervention: Group A: placebo of fruit juice
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Group C: 30 g d‐1 supplementary dietary fibre as wheat bran in bread
Number of subjects: 69